Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia (PRP)
Androgenetic Alopecia, Alopecia, Hair Loss
About this trial
This is an interventional treatment trial for Androgenetic Alopecia focused on measuring Alopecia, Androgenetic Alopecia, Alopecia, Male Pattern, Hair loss, Platelet-Rich Plasma, Alopecia, Female Pattern, placebo, double-blind
Eligibility Criteria
Inclusion Criteria:
- Patients ≥18 years and < 65 years
- Male patients with a clinical diagnosis of AGA (stage II to V according to the Hamilton-Norwood Scale)
- Female patients with a clinical diagnosis of AGA (stage I to III according to Ludwig Classification)
Exclusion Criteria:
- Patients with other types of alopecia, other than AGA
- Fasting < 3h prior of each injection
- Use of nonsteroidal anti-inflammatory drugs one week before treatment.
- Platelet count < 150 000 μL
- Alterations of coagulation
- Heavy smokers (> 20 cigarettes/day)
- Medications: anticoagulants/ acetylsalicylic acid
- Patient unable to accomplishing all fases of treatment
Sites / Locations
- Universitat Internacional Catalunya
Arms of the Study
Arm 1
Experimental
PRP/Saline
PRP/Saline Briefly, for PRP preparation, approximately 18 mL of blood from each patient is drawn into a tube containing 3,8 % sodium citrate. The tubes were centrifuged at 450 g for 8 minutes, resulting in three basic layers: an erythrocyte layer at the bottom of the tube, a PRP layer in the middle, and a platelet-poor plasma (PPP) layer at the top of the tube. After removing the platelet-poor plasma (PPP) layer, the PRP is obtained, activated with 10 % calcium chloride. In the same patient, PRP will be injected to half-head and in the other half-head will be injected with saline solution (placebo). This study includes 4 visits: 3 visits (with 1-month interval) and 1 visit of follow-up (month 6).